Healthcare ❯Pharmaceuticals ❯Clinical Trials ❯Regulatory Approval
Novo Nordisk's weight-loss drug Wegovy demonstrated significant benefits for patients with diabetes and heart failure, potentially expanding its use beyond obesity management.